Resources Repository
-
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Health Outcomes | Health/Medicine | Health Systems | Chronic Disease/Risk | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
Working PaperPublication 2018Valuing Mortality Risk Reductions in Global Benefit-Cost Analysis
Increasing life expectancy is a major goal of many policies implemented around the world. As …
Increasing life expectancy is a major goal of many policies implemented around the world. As a result, the value of reducing mortality risk has been extensively studied and several organizations have developed recommendations for estimating these values in benefit-cost analysis. However, both the recommendations and the underlying research primarily address high-income settings, raising questions about the extent to which the results are applicable in low- and middle-income countries. The recommendations are also diverse, reflecting differing…
Health Outcomes | Health/Medicine | Social Determinants | Preferences/Values | Priority Setting/Ethics | Decision Analysis | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance | Global -
Working PaperPublication 2018Valuing Nonfatal Health Risk Reductions
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- …
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- and middle-income countries. The approach for valuation ideally would be based on estimates of individuals’ willingness to pay for changes in their own risks. However, high quality valuation research is not available for many nonfatal conditions even in high-income settings. Typically, two approaches are used either alone or in combination as rough proxies. The first involves applying an estimate of…
Health Outcomes | Health/Medicine | Social Determinants | Preferences/Values | Priority Setting/Ethics | Decision Analysis | Benefit-Cost Analysis | Policy/Regulation | Economics/Finance | Global | Critical Thinking/Analysis -
GuidelinesPublication 2016Decision Models in Clinical Preventive Services Recommendations
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on …
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on comprehensive systematic reviews of the best available evidence. Decision models provide a complementary, quantitative approach to support the USPSTF as it deliberates about the evidence and develops recommendations for clinical and policy use. This article describes the rationale for using modeling, an approach to selecting topics for modeling, and how modeling may inform recommendations about clinical preventive services.
Health Outcomes | Health/Medicine | Health Systems | Evidence Synthesis | Mathematical Models | Decision Analysis | Policy/Regulation | North America -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Health Outcomes | Health/Medicine | Health Systems | Preferences/Values | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Science/Technology | North America | Europe